

# Desmoplastic Small Round Cell Tumors (DSRCTS) Market to witness growth by 2032, estimates DelveInsight

*Desmoplastic Small Round Cell Tumors companies are Eli Lilly, Y-mAbs, Novartis, Daiichi Sankyo, Genentech, NantCell, MacroGenics, Pyramid Biosciences, others.*


ALBANY, NEW YORK, UNITED STATES, April 1, 2024 /EINPresswire.com/ -- DelveInsight's "Desmoplastic Small Round Cell Tumors (DSRCTS) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Desmoplastic Small Round Cell Tumors (DSRCTS), historical and forecasted epidemiology as well as the Desmoplastic Small Round Cell Tumors (DSRCTS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Desmoplastic Small Round Cell Tumors (DSRCTS) market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Desmoplastic Small Round Cell Tumors (DSRCTS) market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Desmoplastic Small Round Cell Tumors (DSRCTS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Desmoplastic Small Round Cell Tumors (DSRCTS) market.

Request for a Free Sample Report @ [Desmoplastic Small Round Cell Tumors \(DSRCTS\) Market Forecast](#)

Some facts of the Desmoplastic Small Round Cell Tumors (DSRCTS) Market Report are:

- According to DelveInsight, Desmoplastic Small Round Cell Tumors (DSRCTS) market size is expected to grow at a decent CAGR by 2032.
- Leading Desmoplastic Small Round Cell Tumors (DSRCTS) companies working in the market are Eli Lilly and Company, Y-mAbs Therapeutics, Epizyme, Novartis Pharmaceuticals, Daiichi Sankyo,



Genentech, NantCell, Inc., Salarius Pharmaceuticals, MacroGenics, Pyramid Biosciences, among others.

- Key Desmoplastic Small Round Cell Tumors (DSRCTS) Therapies expected to launch in the market are Ramucirumab, Cyclophosphamide, Vinorelbine, Imatinib mesilate, PBI-200, AMG 479, Enoblituzumab, and others.
- On March 2024, Eli Lilly and Company announced results of a Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

### Desmoplastic Small Round Cell Tumors (DSRCTS) Overview

Desmoplastic Small Round Cell Tumors (DSRCTs) are rare and aggressive cancers that typically affect children, adolescents, and young adults, predominantly males. These tumors arise from mesenchymal stem cells and often manifest as multiple masses within the abdomen or pelvis. DSRCTs are characterized by small, round blue cells surrounded by dense fibrous tissue, hence the name "desmoplastic." Symptoms vary but may include abdominal pain, bloating, and weight loss. Diagnosis typically involves imaging studies, biopsy, and molecular testing to confirm the presence of specific genetic mutations, notably the EWSR1-WT1 fusion gene. Treatment usually involves a multimodal approach, including surgery, chemotherapy, and radiation therapy. Despite advancements in therapy, DSRCTs have a poor prognosis due to their aggressive nature and propensity for metastasis. Clinical trials and research are ongoing to improve outcomes for patients with this challenging disease.

Learn more about Desmoplastic Small Round Cell Tumors (DSRCTS) treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ [https://www.delveinsight.com/report-store/desmoplastic-small-round-cell-tumors-market?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=apr](https://www.delveinsight.com/report-store/desmoplastic-small-round-cell-tumors-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr)

### Desmoplastic Small Round Cell Tumors (DSRCTS) Market

The Desmoplastic Small Round Cell Tumors (DSRCTS) market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Desmoplastic Small Round Cell Tumors (DSRCTS) market trends by analyzing the impact of current Desmoplastic Small Round Cell Tumors (DSRCTS) therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Desmoplastic Small Round Cell Tumors (DSRCTS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Desmoplastic Small Round Cell Tumors (DSRCTS) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Desmoplastic Small Round Cell Tumors (DSRCTS) market in 7MM is expected to witness a major change in the study period 2019-2032.

## Desmoplastic Small Round Cell Tumors (DSRCTS) Epidemiology

The Desmoplastic Small Round Cell Tumors (DSRCTS) epidemiology section provides insights into the historical and current Desmoplastic Small Round Cell Tumors (DSRCTS) patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Desmoplastic Small Round Cell Tumors (DSRCTS) market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Desmoplastic Small Round Cell Tumors (DSRCTS) Epidemiology @ [Desmoplastic Small Round Cell Tumors \(DSRCTS\) Market Dynamics and Trends](#)

## Desmoplastic Small Round Cell Tumors (DSRCTS) Drugs Uptake

This section focuses on the uptake rate of the potential Desmoplastic Small Round Cell Tumors (DSRCTS) drugs recently launched in the Desmoplastic Small Round Cell Tumors (DSRCTS) market or expected to be launched in 2019-2032. The analysis covers the Desmoplastic Small Round Cell Tumors (DSRCTS) market uptake by drugs, patient uptake by therapies, and sales of each drug.

Desmoplastic Small Round Cell Tumors (DSRCTS) Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Desmoplastic Small Round Cell Tumors (DSRCTS) market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

## Desmoplastic Small Round Cell Tumors (DSRCTS) Pipeline Development Activities

The Desmoplastic Small Round Cell Tumors (DSRCTS) report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Desmoplastic Small Round Cell Tumors (DSRCTS) key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Desmoplastic Small Round Cell Tumors (DSRCTS) pipeline development activities @ [Desmoplastic Small Round Cell Tumors Therapies and Drugs](#)

## Desmoplastic Small Round Cell Tumors (DSRCTS) Therapeutics Assessment

Major key companies are working proactively in the Desmoplastic Small Round Cell Tumors (DSRCTS) Therapeutics market to develop novel therapies which will drive the Desmoplastic Small Round Cell Tumors (DSRCTS) treatment markets in the upcoming years are Eli Lilly and Company, Y-mAbs Therapeutics, Epizyme, Novartis Pharmaceuticals, Daiichi Sankyo, Genentech, NantCell, Inc., Salarius Pharmaceuticals, MacroGenics, Pyramid Biosciences, among others.

## Desmoplastic Small Round Cell Tumors (DSRCTS) Report Key Insights

1. Desmoplastic Small Round Cell Tumors (DSRCTS) Patient Population
2. Desmoplastic Small Round Cell Tumors (DSRCTS) Market Size and Trends

3. Key Cross Competition in the Desmoplastic Small Round Cell Tumors (DSRCTS) Market
4. Desmoplastic Small Round Cell Tumors (DSRCTS) Market Dynamics (Key Drivers and Barriers)
5. Desmoplastic Small Round Cell Tumors (DSRCTS) Market Opportunities
6. Desmoplastic Small Round Cell Tumors (DSRCTS) Therapeutic Approaches
7. Desmoplastic Small Round Cell Tumors (DSRCTS) Pipeline Analysis
8. Desmoplastic Small Round Cell Tumors (DSRCTS) Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Desmoplastic Small Round Cell Tumors (DSRCTS) Market

## Table of Contents

1. Key Insights
2. Executive Summary
3. Desmoplastic Small Round Cell Tumors (DSRCTS) Competitive Intelligence Analysis
4. Desmoplastic Small Round Cell Tumors (DSRCTS) Market Overview at a Glance
5. Desmoplastic Small Round Cell Tumors (DSRCTS) Disease Background and Overview
6. Desmoplastic Small Round Cell Tumors (DSRCTS) Patient Journey
7. Desmoplastic Small Round Cell Tumors (DSRCTS) Epidemiology and Patient Population
8. Desmoplastic Small Round Cell Tumors (DSRCTS) Treatment Algorithm, Current Treatment, and Medical Practices
9. Desmoplastic Small Round Cell Tumors (DSRCTS) Unmet Needs
10. Key Endpoints of Desmoplastic Small Round Cell Tumors (DSRCTS) Treatment
11. Desmoplastic Small Round Cell Tumors (DSRCTS) Marketed Products
12. Desmoplastic Small Round Cell Tumors (DSRCTS) Emerging Therapies
13. Desmoplastic Small Round Cell Tumors (DSRCTS) Seven Major Market Analysis
14. Attribute Analysis
15. Desmoplastic Small Round Cell Tumors (DSRCTS) Market Outlook (7 major markets)
16. Desmoplastic Small Round Cell Tumors (DSRCTS) Access and Reimbursement Overview
17. KOL Views on the Desmoplastic Small Round Cell Tumors (DSRCTS) Market
18. Desmoplastic Small Round Cell Tumors (DSRCTS) Market Drivers
19. Desmoplastic Small Round Cell Tumors (DSRCTS) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

## About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Ankit Nigam

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/699687528>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.